Pembrolizumab (Genetical Recombination) (100㎎4㎖/1vial) 4,700 vials,and 44 other contracts

2026-11-03

Official in charge of disbursement of the procuring entity : KUMANOGOH Atsushi, President, The University of Osaka Classification of the products to be procured : Nature and quantity of the products to be purchased : A Pembrolizumab (Genetical Recombination) (100㎎4㎖/1vial) 4,70 vials B Bevacizumab (Genetical Recombination) (100㎎4㎖/1vial) 97 vials C Bevacizumab (Genetical Recombination) (400㎎16㎖/1vial) 90 vials D Ustekinumab (Genetical Recombination) (45㎎0.5㎖/1syringe) 92 syringes E Infliximab (Genetical Recombination) (100㎎/1vial) 1,20 vials F Pertuzumab (Genetical Recombination) (420㎎14㎖/1vial) 37 vials G Eculizumab (Genetical Recombination) (300㎎30㎖/1vial) 16 vials H Agalsidase Beta (Genetical Recombination) (35㎎/1vial) 25 vials I Pegfilgrastim (Genetical Recombination) (3.6㎎0.36㎖/1syringe) 86 syringes J Ipilimumab (Genetical Recombination) (50㎎10㎖/1vial) 29 vials K Atezolizumab (Genetical Recombination) (1,200㎎20㎖/1vial) 32 vials L Durvalumab (Genetical Recombination) (500㎎10㎖/1vial) 1,59 vials M Agalsidase Beta (Genetical Recombination) [Agalsidase Beta Biosimilar 1] (35㎎/1vial) 4 vials N Nivolumab (Genetical Recombination) (240㎎24㎖/1vial) 1,82 vials O Elapegademase (Genetical Recombination) (2.4㎎1.5㎖/1vial) 10 vials P Emicizumab (Genetical Recombination) (150㎎1.0㎖/1vial) 9 vials Q Tisagenlecleucel bag R Avelumab (Genetical Recombination) (200㎎10㎖/1vial) 41 vials Irinotecan Hydrochloride Hydrate (43㎎10㎖/1vial) 35 vials T Aflibercept (Genetical Recombination) (2㎎0.05㎖/1syringe) 3,20 syringes U Satralizumab (Genetical Recombination) (120㎎1.0㎖/1syringe) 10 syringes V Polatuzumab Vedotin (Genetical Recombination) (38㎎/1vial) 33 vials W Lisocabtagene maraleucel 1 sets X Ravulizumab (Genetical Recombination) (300㎎3㎖/1vial) 1,99 vials Y Inebilizumab (Genetical Recombination) (100㎎10㎖/1vial×3vials) 3 cases Z pH4-Treated Normal Human Immunoglobulin (5g50㎖/1vial) 1,64 vials AA Efgartigimod Alfa (Genetical Recombination) (400㎎20㎖/1vial) 43 vials AB Faricimab (Genetical Recombination) (28.8㎎0.24㎖/1vial) 25 vials AC Idecabtagene vicleucel bags AD Sutimlimab (Genetical Recombination) (1,100㎎22㎖/1vial) 32 vials AE Vutrisiran Sodium (25㎎0.5㎖/1syringe) 4 syringes AF Axicabtagene ciloleucel bags AG Pertuzumab (Genetical Recombination) ･ Trastuzumab (Genetical Recombination) ･ Vorhyaluronidase Alfa (Genetical Recombination) (600㎎･600㎎･20000U10㎖/1vial) 40 vials AH Evinacumab (Genetical Recombination) (345㎎2.3㎖/1vial) 8 vials AI Efgartigimod Alfa (Genetical Recombination) ･ Vorhyaluronidase Alfa (Genetical Recombination) (1,008㎎･11200U5.6㎖/1vial) 14 vials AJ Crovalimab (Genetical Recombination) (340㎎2.0㎖/1vial) 10 vials AK Letermovir (240㎎/1capsule 14capsules/1case) 56 cases AL Paclitaxel (100㎎/1vial) 2,70 vials AM Ramucirumab (Genetical Recombination) (500㎎50㎖/1vial) 30 vials AN Trastuzumab Deruxtecan (Genetical Recombination) (107㎎/1vial) 69 vials AO Teprotumumab (Genetical Recombination) (524㎎/1vial) 60 vials AP Tofersen (100㎎/1vial) 9 vials AQ Aflibercept (Genetical Recombination) (8㎎0.07㎖/1syringe) 83 syringes AR Faricimab (Genetical Recombination) (21.0㎎0.175㎖/1syringe) 27 syringes A Denosumab (Genetical Recombination) (120㎎1.0㎖/1syringe) 54 syringes Delivery period : By April, 202 through 3 March, 202 Delivery place : The University of Osaka Hospital and Dental Hospital Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article and of the Regulation concerning the Contract for The University of Osaka, B have the Grade A or Grade B qualification during fiscal 202 in the Kinki area in sales of product for participating in tenders by Single qualification for every ministry and agency, or in tenders by The University of Osaka, C prove to have obtained the first-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices. D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by President. Time limit of tender : 1 : 0 2 March, 202 Contact point for the notice : MATSUO Takenori, Procurement Section, Accounting Division, The University of Osaka Hospital, 2-1 Yamadaoka Suita shi Osaka 565-087 Japan, TEL 06-6879-513 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

Japan

2026-03-26